Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model
- PMID: 16211715
- DOI: 10.1080/00365520510023215
Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model
Abstract
Objective: Current prognostic models in primary biliary cirrhosis (PBC) have low precision, partly due to the restricted inclusion criteria of some cohorts used for modelling but also because of the prolonged natural course of the disease. It is hypothesized that better precision could be achieved with a staged model, using ascites or peripheral oedema as a new starting-point for prediction.
Material and methods: The study was based on an established database of 289 consecutive patients, followed between 1977 and 1998. Stepwise Cox regression was used to construct a staged model based on 143 patients who first developed ascites (n=111) or peripheral oedema (n=32) at entry or during subsequent follow-up. The model was compared with published models using graphical methods and receiver operating characteristics (ROCs).
Results: Mean time from clinical diagnosis of ascites or peripheral oedema to death was 3.1 years. The following variables had independent prognostic significance: log10(bilirubin) (p<0.001), albumin (p<0.001), age (p<0.001) and history of encephalopathy (p<0.001). Goodness of fit showed that the survival probabilities predicted by the Ascites Stage Model fitted well with the observed data. The Ascites Stage Model (ROC 0.8324 (SE 0.0348)) was a better predictor of survival than the Mayo long-term model (ROC 0.7833 (SE 0.0397)), the Mayo Repeated Patient Visits Model (ROC 0.7779 (SE 0.0399)) and the Royal Free PBC Prognostic Model (ROC 0.7785 (SE 0.0396)).
Conclusions: The Ascites Stage Model gives a better survival estimate for PBC patients once they have developed ascites or peripheral oedema compared with the current models, and demonstrates an advantage of staged models in diseases with a prolonged natural history.
Similar articles
-
Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach.Aliment Pharmacol Ther. 2010 Mar;31(5):573-82. doi: 10.1111/j.1365-2036.2009.04215.x. Epub 2009 Dec 10. Aliment Pharmacol Ther. 2010. PMID: 20003096
-
Major clinical events, signs and severity assessment scores related to actual survival in patients who died from primary biliary cirrhosis. A long-term historical cohort study.Hepatogastroenterology. 1999 Jan-Feb;46(25):108-15. Hepatogastroenterology. 1999. PMID: 10228773
-
Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits.Hepatology. 1994 Jul;20(1 Pt 1):126-34. doi: 10.1016/0270-9139(94)90144-9. Hepatology. 1994. PMID: 8020881
-
Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis.Intern Med. 2013;52(14):1553-9. doi: 10.2169/internalmedicine.52.0010. Epub 2013 Jul 15. Intern Med. 2013. PMID: 23857086 Review.
-
Survival algorithms and outcome analysis in primary biliary cirrhosis.Semin Liver Dis. 1997 May;17(2):147-58. doi: 10.1055/s-2007-1007193. Semin Liver Dis. 1997. PMID: 9170202 Review.
Cited by
-
Diagnosis and treatment of primary biliary cholangitis.United European Gastroenterol J. 2020 Jul;8(6):667-674. doi: 10.1177/2050640620919585. Epub 2020 Apr 16. United European Gastroenterol J. 2020. PMID: 32299307 Free PMC article. Review.
-
Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy.Biomed Res Int. 2013;2013:139763. doi: 10.1155/2013/139763. Epub 2013 Jul 24. Biomed Res Int. 2013. PMID: 23984317 Free PMC article.
-
Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.Aliment Pharmacol Ther. 2013 Dec;38(11-12):1354-64. doi: 10.1111/apt.12522. Epub 2013 Oct 5. Aliment Pharmacol Ther. 2013. PMID: 24117847 Free PMC article.
-
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Gut. 2018 Sep;67(9):1568-1594. doi: 10.1136/gutjnl-2017-315259. Epub 2018 Mar 28. Gut. 2018. PMID: 29593060 Free PMC article.
-
Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12. Am J Gastroenterol. 2018. PMID: 29231188
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical